MeMed today announced DTRA’s expanded commitment to their point-of-care immunoassay platform and ground breaking bacterial versus viral host-response test.
Read more on PR Newswire here.
MeMed today announced DTRA’s expanded commitment to their point-of-care immunoassay platform and ground breaking bacterial versus viral host-response test.
Read more on PR Newswire here.
![[OurCrowd in Tech Crunch] OurCrowd makes the first 8 investments from its Israel Resilience Fund](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
